Accueil   Diary - News   All news Adocia Announces Approval to Start a Phase IIa Clinical Study

Adocia Announces Approval to Start a Phase IIa Clinical Study

Adocia announced that BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte), the German regulatory agency for drugs and medical devices, has approved the initiation of a Phase IIa clinical study of HinsBet®, a fast-acting formulation of human insulin. HinsBet is a new type of prandial insulin, developed using the Company’s proprietary BioChaperone® technology, that has been designed to reconcile the performance of insulin analogs with the cost-effectiveness of human insulin.

 

Read the press release